P Karlsson1, B F Cole2, B H Chua3, K N Price4, J Lindtner5, J P Collins6, A Kovács7, B Thürlimann8, D Crivellari9, M Castiglione-Gertsch10, J F Forbes11, R D Gelber12, A Goldhirsch13, G Gruber14. 1. Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden. Electronic address: per.karlsson@oncology.gu.se. 2. Department of Mathematics and Statistics College of Engineering and Mathematical Sciences, University of Vermont, Burlington; IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA. 3. Department of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. 4. IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA; Frontier Science and Technology Research Foundation, Boston, USA. 5. The Institute of Oncology, Ljubljana, Slovenia. 6. Department of Surgery, Royal Melbourne Hospital, Victoria, Australia. 7. Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden. 8. The Breast Center, Kantonsspital, St Gallen, Switzerland and Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. 9. Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy. 10. Gyneco-Oncology Unit, University Hospital, Geneva, Switzerland. 11. Australian New Zealand Breast Cancer Trials Group, University of Newcastle, Calvary Mater Newcastle, Newcastle, Australia. 12. IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, USA; Frontier Science and Technology Research Foundation, Boston, USA; Harvard School of Public Health and Harvard Medical School, Boston, USA. 13. European Institute of Oncology, Milan, Italy; Swiss Center for Breast Health, Sant'Anna Clinics, Lugano-Sorengo. 14. Institut fuer Radiotherapie, Klinik Hirslanden, Zürich, Switzerland.
Abstract
BACKGROUND: Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and target for postmastectomy radiotherapy (PMRT). PATIENTS AND METHODS: Local, axillary and supraclavicular recurrences were evaluated in 8106 patients enrolled in 13 randomized trials. Patients received chemotherapy and/or endocrine therapy and mastectomy without radiotherapy. Median follow-up was 15.2 years. RESULTS: Ten-year cumulative incidence for chest wall recurrence of >15% was seen in patients aged <40 years (16.1%), with ≥4 positive nodes (16.5%) or 0-7 uninvolved nodes (15.1%); for supraclavicular failures >10%: ≥4 positive nodes (10.2%); for axillary failures of >5%: aged <40 years (5.1%), unknown primary tumor size (5.2%), 0-7 uninvolved nodes (5.2%). In patients with 1-3 positive nodes, 10-year cumulative incidence for chest wall recurrence of >15% were age <40, peritumoral vessel invasion or 0-7 uninvolved nodes. Age, number of positive nodes and number of uninvolved nodes were significant parameters for each locoregional relapse site. CONCLUSION: PMRT to the chest wall and supraclavicular fossa is supported in patients with ≥4 positive nodes. With 1-3 positive nodes, chest wall PMRT may be considered in patients aged <40 years, with 0-7 uninvolved nodes or with vascular invasion. The findings do not support PMRT to the dissected axilla.
BACKGROUND: Rates and risk factors of local, axillary and supraclavicular recurrences can guide patient selection and target for postmastectomy radiotherapy (PMRT). PATIENTS AND METHODS: Local, axillary and supraclavicular recurrences were evaluated in 8106 patients enrolled in 13 randomized trials. Patients received chemotherapy and/or endocrine therapy and mastectomy without radiotherapy. Median follow-up was 15.2 years. RESULTS: Ten-year cumulative incidence for chest wall recurrence of >15% was seen in patients aged <40 years (16.1%), with ≥4 positive nodes (16.5%) or 0-7 uninvolved nodes (15.1%); for supraclavicular failures >10%: ≥4 positive nodes (10.2%); for axillary failures of >5%: aged <40 years (5.1%), unknown primary tumor size (5.2%), 0-7 uninvolved nodes (5.2%). In patients with 1-3 positive nodes, 10-year cumulative incidence for chest wall recurrence of >15% were age <40, peritumoral vessel invasion or 0-7 uninvolved nodes. Age, number of positive nodes and number of uninvolved nodes were significant parameters for each locoregional relapse site. CONCLUSION: PMRT to the chest wall and supraclavicular fossa is supported in patients with ≥4 positive nodes. With 1-3 positive nodes, chest wall PMRT may be considered in patients aged <40 years, with 0-7 uninvolved nodes or with vascular invasion. The findings do not support PMRT to the dissected axilla.
Authors: M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; C Fussl; W Haase; W Harms; M D Piroth; R Souchon; F Wenz; R Sauer Journal: Strahlenther Onkol Date: 2014-03-05 Impact factor: 3.621
Authors: Clayton Hess; Anna Lee; Kari Fish; Megan Daly; Rosemary D Cress; Jyoti Mayadev Journal: Clin Breast Cancer Date: 2014-12-01 Impact factor: 3.225
Authors: Irene L Wapnir; Karen N Price; Stewart J Anderson; André Robidoux; Miguel Martín; Johan W R Nortier; Alexander H G Paterson; Mothaffar F Rimawi; István Láng; José Manuel Baena-Cañada; Beat Thürlimann; Eleftherios P Mamounas; Charles E Geyer; Shari Gelber; Alan S Coates; Richard D Gelber; Priya Rastogi; Meredith M Regan; Norman Wolmark; Stefan Aebi Journal: J Clin Oncol Date: 2018-02-14 Impact factor: 50.717
Authors: Amy J Xu; Carl J DeSelm; Alice Y Ho; Erin F Gillespie; Lior Z Braunstein; Atif J Khan; Beryl McCormick; Simon N Powell; Oren Cahlon Journal: Adv Radiat Oncol Date: 2019-03-01